Flowers

Our
Early Cancer Detection
Blood Tests

Freenome aims to detect cancer earlier and make cancer screening more accessible through standard blood tests.

Using a Standard Blood Draw for Early Cancer Detection

Today, when people visit their doctors for annual checkups, they often take blood tests to determine their cholesterol and blood sugar levels. What if one of those blood tests could screen for cancer as well?

Our goal is to meet patients where they are. We are developing blood tests to be easy to administer and fit within today’s evolving healthcare framework. Our tests are developed using our comprehensive multiomics platform to enable us to detect the body’s earliest warning signs of cancer.

Learn more about our multiomics platform

Our Colorectal Cancer (CRC) Blood Test

Our first blood test in development is for colorectal cancer (CRC)—the second deadliest cancer in the United States.1 Together, we can change that statistic. Because, even though CRC is one of the most fatal cancers today, it is also one of the most treatable when detected early.1

Despite multiple screening options, more than one-third of people who are eligible for CRC don’t get screened.2 We seek to improve this by developing an accessible blood test that makes it easier to get screened and, therefore, detect CRC in its earliest stages.

Our CRC blood test is currently being validated through PREEMPT CRC®, the largest clinical study validating a blood-based colorectal screening test.

Learn more about Our FDA Clinical study, preempt CRC

Our Multi-Cancer Tests:
One Size Does Not Fit All

CRC is just one of many cancers for which we are developing early detection blood tests.

A lot of people may not realize that there are more than 100 cancers—making detection, diagnosis, and treatment not a one-size-fits-all process. That’s why Freenome is developing a tailored approach for our multi-cancer screening tests. This ensures each test is optimized for different cancer signals, screening goals, and diagnostic and care pathways, to ultimately improve patient outcomes. The Vallania Study and The Sanderson Study are our multi-cancer clinical studies currently enrolling patients across the United States

LEARN MORE ABOUT why one size does not fit all LEARN MORE ABOUT our multiomics platform LEARN ABOUT our multi-cancer clinical studies

Sources

  1. National Center for Health Statistics, CDC, SEER program
  2. Richardson LC, King JB, Thomas CC, Richards TB, Dowling NF, Coleman King S. Adults Who Have Never Been Screened for Colorectal Cancer, Behavioral Risk Factor Surveillance System, 2012 and 2020. Prev Chronic Dis 2022;19:220001. DOI: http://dx.doi.org/10.5888/pcd19.220001